22 citations
,
May 2003 in “Planta Medica” Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.
88 citations
,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
June 2017 in “Journal of The American Academy of Dermatology” Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
7 citations
,
May 1983 in “Geburtshilfe und Frauenheilkunde” Intramuscular cyproterone acetate effectively treats hirsutism and improves skin conditions in women with hyperandrogenism.
May 2022 in “Endocrine Abstracts” Cyproterone acetate therapy improved hair loss and reduced testosterone levels in a menopausal woman.
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
May 2024 in “Australasian journal of dermatology” Bicalutamide is more effective and safer than spironolactone for treating female hair loss.
17 citations
,
April 1997 in “Archives of dermatology” The document describes a treatment for excessive hair growth in a teenage girl using medication and birth control, but does not report the results.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
7 citations
,
October 2015 in “Actas Dermo-Sifiliográficas” New treatments for Frontal Fibrosing Alopecia show promise, especially finasteride and dutasteride, with most patients seeing improvement or stabilization.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
Antimalarial agents are effective for LPP, and intralesional steroids are effective for FFA.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
December 2021 in “Daehanhanuihakoeji” The traditional herbal formulas Yongdamsagan-Tang and Paljung-san, along with the drug finasteride, can reduce inflammation and may work together without affecting each other's effectiveness against benign prostatic hyperplasia.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.